Cancer cells package immunosuppressive PD-L1 into sEVs via UBL3, hindering immunotherapy. Researchers found widely used statins can block this process, offering a new strategy to enhance immune checkpoint therapies by reducing circulating immunosuppressive PD-L1.
Immunotherapy efficacy can be boosted by preserving lymph nodes, crucial for T cell training. Research suggests lymph node removal during surgery may hinder cancer treatment response. Gut bacteria also influence immunotherapy.
Johns Hopkins researchers found boosting immune defenses prevents cancer recurrence and boosts survival. Activating T and B cells transforms 'cold' tumors, enhancing immunotherapy and radiation treatment effectiveness.
